Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease
Tokyo, Japan and Cambridge, UK, 4 November 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”; TSE: 4565) today announces that its subsidiary, Nxera Pharma UK Ltd, has entered into an exclusive global license agreement (the “Agreement”) with AbbVie Inc. (“AbbVie”) for Nxera’s EP4 agonist program including NXE0033744, a novel small molecule EP4 receptor agonist discovered by Nxera. Under the Agreement, AbbVie will receive exclusive rights to develop and commercialize NXE0033744 worldwide in inflammatory bowel disease (IBD).
Covered in this story
Analyst targets on AbbVie
- UBS: $276 → $275 by Oct 2027 · Neutral via GuruFocus
- Bank of America: $262 → $289 by Sep 2027 · Buy via AOL.com
- Wolfe Research: $263 → $300 by Sep 2027 · Outperform via Yahoo Finance
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Dalsna Finance is currently tracking 50 stories mentioning AbbVie, the earliest published 29 Jul 2026.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.